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Cangrelor and Bivalirudin*
Gilles Montalescot, MD, PHD, Gérard Helft, MD, PHDB ivalirudin and cangrelor are 2 intravenousdrugs, 1 for anticoagulation and the other forantiplatelet therapy, with a rapid onset of
action, thus in theory perfectly adapted to percuta-
neous coronary intervention (PCI) that requires
simultaneous thrombin and platelet inhibition. These
effects are especially needed for mechanical coronary
reperfusion of acute patients such as those presenting
with ST-segment elevation myocardial infarction
(STEMI). The short half-lives and good tolerance of
these 2 drugs add to the attractiveness of their proﬁle
in the contemporary era of expeditious and safety-
oriented care.
Bivalirudin anticoagulation has been associated
with a reduction of major bleeding complications,
the magnitude of which varies based on whether
glycoprotein IIb/IIIa inhibitors are used in the con-
trol arm with unfractionated heparin (1). There is
no signiﬁcant reduction of major bleeding when
glycoprotein IIb/IIIa inhibitors are used provision-
ally with both anticoagulant strategies of unfractio-
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Inspire MD, AstraZeneca, and Boehringer Ingelheim.IIb/IIIa inhibitors are mostly used provisionally. A
bivalirudin-based regimen compared with a heparin-
based regimen for PCI increases ischemic events and
stent thrombosis (1). Any strategy that could reduce
major thrombotic events after PCI would be welcome
in bivalirudin-oriented catheterization laboratories.
The use of the more potent P2Y12 receptor antagonists
prasugrel and ticagrelor in patients receiving bivalir-
udin is an option but was not conﬁrmed in the EURO-
MAX trial (European Ambulance Acute Coronary
Syndrome [ACS] Angiography) (61% use of prasugrel or
ticagrelor) and HEAT-PPCI study (How Effective Are
Antithrombotic Therapies in Primary Percutaneous
Coronary Intervention) (89% use of prasugrel or tica-
grelor) studies, both of which showed a persistent
excess of stent thrombosis (2,3). Cangrelor, more
potent and more rapidly active than prasugrel and
ticagrelor, is another option, considering the demon-
strated reduction of ischemic events (20%) and stent
thrombosis (40%) compared with clopidogrel in the
CHAMPION-PHOENIX trial (A Clinical Trial Comparing
Cangrelor to Clopidogrel Standard Therapy in Subjects
Who Required Percutaneous Coronary Intervention)
and ameta-analysis (4,5). These attractive results were
associated with no excess bleeding but also no reduc-
tion in mortality. The study reported in this issue of
JACC: Cardiovascular Interventions examines this
marriage of bivalirudin and cangrelor in the
CHAMPION-PHOENIX trial (6).SEE PAGE 424In this subset analysis of patients receiving bivalir-
udin (19% of the CHAMPION-PHOENIX population),
cangrelor compared with clopidogrel signiﬁcantly
reduced ischemic events as well as stent thrombosis
to the same magnitude as in the main trial. This
ﬁnding does not mean that cangrelor can eliminate
the excess of stent thrombosis related to bivalirudin
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435use. Indeed, a similar effect of cangrelor was reported
with unfractionated heparin in the initial publication
(p value for interaction ¼ 0.51). Are these ﬁndings
relevant? It is noteworthy that this subset analysis
applies almost exclusively to patients from the United
States (93%) when the global study recruited the
majority of patients outside the United States (63%)
where anticoagulants other than bivalirudin were
generally used. So the ﬁndings are relevant to these
catheterization laboratories using bivalirudin. The
cangrelor effect is preserved but does not eliminate
the excess risk of stent thrombosis related to bivalir-
udin itself. In the rest of the world where other an-
ticoagulants are used, the cangrelor effect is similarly
present. The survival curves show clearly the timing
of the cangrelor effect, preventing stent thrombosis
in the ﬁrst 3 h after PCI, exactly as in the ATLANTIC
study (A 30 Day Study to Evaluate Efﬁcacy and Safety
of Pre-hospital vs. In-hospital Initiation of Ticagrelor
Therapy in STEMI Patients Planned for Percutaneous
Coronary Intervention [PCI]) when using pre-
hospital (rather than in-hospital) ticagrelor in pri-
mary PCI (7). The timing of P2Y12 inhibition appears
to be a key modulator of stent thrombosis and is
best obtained with an early oral load of ticagrelor
or later intravenous administration of cangrelor.
Neither strategy is associated with increased bleed-
ing. Late administration of clopidogrel, particu-
larly in STEMI, would be the least effective strategy
for the prevention of post-procedural thrombotic
events.
There are obvious regional differences in the use of
bivalirudin, which has replaced unfractionated hep-
arin in places where glycoprotein IIb/IIIa inhibitors
were commonly used, but was seen as less useful andtoo expensive in places where glycoprotein IIb/IIIa
inhibitors were not as popular. In addition to the
stent thrombosis and cost issues, practicality was also
seen as a limiting factor for bivalirudin (1 bolus,
2 infusion doses, prolonged infusion after PCI). The
recent European Guidelines on Myocardial Revascu-
larization give the same Class IIa recommendation to
bivalirudin and enoxaparin, the latter being another
alternative to unfractionated heparin, without the
stent thrombosis, cost, and practicality concerns of
bivalirudin (8–10).
In conclusion, the arranged marriage of bivalirudin
and cangrelor presupposes that they are comple-
mentary and that the 2 are perfectly matched, but, as
we indicate, nothing suggests such complementarity
here. The same company selling both drugs may want
to arrange this marriage but is fully aware that the
physicians can always refuse this marriage and sim-
ply look for another choice. This arranged marriage
may not be forced, especially when the cost is taken
into account, knowing that effectiveness is not
guaranteed. Finally, 1 reason for marrying bivalirudin
and cangrelor may well be a cultural trademark in labs
where the economic pressure is not too important
and where bivalirudin adoption is so pervasive, there
is reluctance to change. Elsewhere, tolerance of a
different type of marriage will be necessary, accept-
ing a selection of patients for cangrelor and routine
anticoagulant strategies other than bivalirudin.
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